Conexeu Sciences Inc. CNXU
NASDAQ
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 209.06% | 38.75% | |||
| Depreciation & Amortization | -52.63% | 78.13% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 210.53% | 37.72% | |||
| Operating Income | -210.53% | -37.72% | |||
| Income Before Tax | -235.27% | -34.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -235.27% | -34.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -235.27% | -34.06% | |||
| EBIT | -210.53% | -37.72% | |||
| EBITDA | -211.81% | -37.57% | |||
| EPS Basic | -155.71% | -30.84% | |||
| Normalized Basic EPS | -155.71% | -30.84% | |||
| EPS Diluted | -155.71% | -30.84% | |||
| Normalized Diluted EPS | -155.71% | -30.84% | |||
| Average Basic Shares Outstanding | 31.12% | 2.43% | |||
| Average Diluted Shares Outstanding | 31.12% | 2.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||